LBBW raises target to EUR 26.50 for Schott Pharma stock
Published on 10/25/2026 at 13:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTargets and reporting dates
- LBBW raised its target from EUR 22.00 to EUR 26.50 on October 12, 2026.
- Second-quarter revenue for the period ended June 30, 2026, rose 9.87 percent to EUR 281.76 million.
- Schott Pharma stock closed at EUR 25.80 on October 23, 2026.
- The next quarterly results are expected on December 10, 2026.
Schott Pharma (ISIN DE000A3ENQ51) had its LBBW price target raised from EUR 22.00 to EUR 26.50 on October 12, 2026, according to Goldesel. The move came after third-quarter revenue had reached EUR 281.76 million, up 9.87 percent from EUR 256.46 million in the comparable period, according to finanzen.ch.
Growth meets a lower earnings measure
The revenue increase covered the quarter ended June 30, 2026, while earnings per share came in at EUR 0.26, down from EUR 0.30 a year earlier, finanzen.ch reported. That combination gives the new target a more demanding test: sales growth has to translate into stronger earnings as well.
Three dated analyst signals
On August 12, 2026, Schott Pharma reported EUR 281.76 million in quarterly revenue. On October 9, 2026, Deutsche Bank cut its rating from Buy to Hold while lifting its target from EUR 23.00 to EUR 25.00, according to Goldesel. On October 12, 2026, LBBW raised its target from EUR 22.00 to EUR 26.50 and maintained its Buy recommendation, the same source reported.
What does the target mean?
The last Xetra price of EUR 25.80 stood 2.64 percent below LBBW's EUR 26.50 target and 3.20 percent above Deutsche Bank's EUR 25.00 target. The contrasting ratings show why the targets should be read alongside the earnings trend rather than as a single market view.
Upcoming dates for investors
The next two financial-calendar entries listed by SCHOTT Pharma are the BNP Midcap CEO Conference on November 17, 2026, and LBBW German Company Day on November 18, 2026, according to SCHOTT Pharma. The next quarterly results are expected on December 10, 2026, according to finanzen.ch.
Stock near its yearly high
Schott Pharma's Xetra price was EUR 25.80 on October 23, 2026, while the 52-week range cited by finanzen.ch ran from EUR 12.62 to EUR 26.20. The stock was therefore 1.53 percent below its 52-week high.
The further course of trading is shown by the continuously updated real-time quote of Schott Pharma stock.
Schott Pharma at a glance
- Company: SCHOTT Pharma AG & Co. KGaA
- ISIN: DE000A3ENQ51
- Ticker: 1SXP
- Primary exchange: Xetra
- Last Xetra price (as of October 23, 2026): EUR 25.80
- Market capitalization: EUR 3.9 billion (as of October 23, 2026)
- 52-week range: EUR 12.62-EUR 26.20 (as of October 23, 2026)
- Sector / Industry: Healthcare / Medical Instruments and Supplies
- Next earnings date: December 10, 2026
Market context: Market report DAX.
